BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 25740267)

  • 1. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
    Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
    Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
    Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
    Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
    Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
    Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
    Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
    Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
    Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.
    Tomita Y; Maeda K; Sugiyama Y
    Clin Pharmacol Ther; 2013 Jul; 94(1):37-51. PubMed ID: 23443754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
    Kitamura S; Maeda K; Wang Y; Sugiyama Y
    Drug Metab Dispos; 2008 Oct; 36(10):2014-23. PubMed ID: 18617601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin.
    Deng JW; Shon JH; Shin HJ; Park SJ; Yeo CW; Zhou HH; Song IS; Shin JG
    Pharm Res; 2008 Aug; 25(8):1807-14. PubMed ID: 18236139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
    Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
    Wang Q; Zheng M; Leil T
    CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):228-238. PubMed ID: 28296193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1.
    Fan L; Zhang W; Guo D; Tan ZR; Xu P; Li Q; Liu YZ; Zhang L; He TY; Hu DL; Wang D; Zhou HH
    Clin Pharmacol Ther; 2008 Mar; 83(3):471-6. PubMed ID: 17851565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of a basolateral transporter in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell monolayer systems.
    Li J; Wang Y; Zhang W; Huang Y; Hein K; Hidalgo IJ
    Drug Metab Dispos; 2012 Nov; 40(11):2102-8. PubMed ID: 22855735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.
    Choi JH; Lee MG; Cho JY; Lee JE; Kim KH; Park K
    Clin Pharmacol Ther; 2008 Feb; 83(2):251-7. PubMed ID: 17568401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
    Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
    Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
    Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
    Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.